Oxycodon-Hcl/Naloxon-Hcl Puren

Active Ingredient:: Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate
Origin:: EU

Oxycodon-Hcl/Naloxon-Hcl Puren (Oxycodone Hydrochloride, Naloxone Hydrochloride Dihydrate)

International sale not permitted. Listed for the domestic market and B2B only.

Oxycodone Hydrochloride, the active ingredient in Oxycodon-Hcl/Naloxon-Hcl Puren, is an opioid analgesic presented as a combination formulation for oral use. It is used to treat moderate to severe pain in adult patients when other analgesics are insufficient.

GNH India supplies Oxycodon-Hcl/Naloxon-Hcl Puren as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Puren Pharma Gmbh & Co. Kg

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Oxycodon-Hcl/Naloxon-Hcl Puren is an opioid analgesic indicated for pain management pathways involving strong opioid receptors.

Acute postoperative pain: provides rapid relief of moderate to severe pain following surgery.
Cancer‑related pain: helps control persistent pain associated with malignant disease.
Chronic non‑cancer pain: used when other treatments have failed to achieve adequate analgesia.

How It Works

The combination delivers oxycodone, a µ‑opioid receptor agonist that mimics endogenous opioids to reduce pain signaling, together with naloxone, a peripheral µ‑opioid antagonist that limits opioid‑induced constipation by blocking receptors in the gastrointestinal tract without affecting central analgesia.

Side Effects

Adverse reactions may occur with opioid therapy and should be monitored.

Common Side Effects

Nausea: mild to moderate upset stomach.
Constipation: reduced bowel motility.
Dizziness: light‑headed feeling.
Somnolence: increased sleepiness.
Dry mouth: reduced salivation.
Pruritus: mild skin itching.

Serious or Rare Side Effects

Respiratory depression: slowed breathing that can be life‑threatening.
Severe hypotension: marked drop in blood pressure.
Acute adrenal insufficiency: rare hormonal imbalance.
Allergic reactions: rash, swelling, or anaphylaxis.
Opioid use disorder: risk of dependence or misuse.
Withdrawal syndrome: symptoms if opioid therapy is abruptly stopped.

Precautions & Warnings

When prescribing Oxycodon-Hcl/Naloxon-Hcl Puren, clinicians should consider several safety measures.

Assess pain severity: confirm that opioid therapy is appropriate.
Evaluate respiratory function: monitor patients with COPD or sleep apnea.
Review medication history: avoid concurrent CNS depressants when possible.
Monitor for signs of dependence: educate patients on proper use.
Adjust dose in renal/hepatic impairment: use lower initial doses.
Store at ambient temperature: keep in original container, protect from moisture and light.

Avoid Interactions

Oxycodon-Hcl/Naloxon-Hcl Puren can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
MAO inhibitors: increase risk of serotonin syndrome.
Strong CYP3A4 inhibitors (e.g., ketoconazole): elevate oxy‑dose plasma levels.

Moderate Interactions (Monitor Closely)

CYP2D6 inhibitors (e.g., fluoxetine): may alter oxycodone metabolism.
Diuretics: can enhance hypotensive effects.
Anticholinergics: may worsen constipation.
Alcohol: additive CNS depression.
Herbal supplements (e.g., St John’s wort): may affect opioid metabolism.

Frequently Asked Questions

Oxycodon-Hcl/Naloxon-Hcl Puren is a combination opioid product indicated for the management of moderate to severe pain, including postoperative pain, cancer‑related pain, and chronic pain that has not responded adequately to non‑opioid therapies.

Oxycodone acts as a µ‑opioid receptor agonist in the central nervous system, mimicking natural endorphins to dampen pain signal transmission, while naloxone remains largely inactive centrally and blocks µ‑receptors in the gut, reducing opioid‑induced constipation.

The prescribed dose is individualized by the treating clinician based on pain severity, prior opioid exposure, and patient-specific factors such as age, renal and hepatic function. Dosage adjustments follow local prescribing guidelines.

Opioid use in pregnancy carries risks of neonatal respiratory depression and possible dependence; naloxone is not well studied in this setting. Breastfeeding is generally discouraged while using strong opioids because the drug can pass into milk. Clinicians should weigh benefits against potential fetal or infant risks.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

The oxycodone‑naloxone combination offers comparable analgesia to pure oxycodone while reducing the incidence of opioid‑induced constipation, a common side effect of many strong opioids. It is often preferred when bowel‑function preservation is a clinical priority.

Store the tablets at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Keep out of reach of children and unauthorized personnel.

The product is supplied as oral tablets that are taken whole with water, usually every 12 hours, or as directed by the prescribing clinician. Swallowing whole ensures proper release of both oxycodone and naloxone.

The most serious risks include respiratory depression, severe hypotension, opioid dependence, and rare allergic reactions. Patients should be monitored for signs of slowed breathing, extreme drowsiness, or any hypersensitivity symptoms.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 10 Oct 2026

Disclaimer

International sale not permitted. Listed for the domestic market and B2B only.

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.